

# Bashkim Kadriu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4220097/publications.pdf>

Version: 2024-02-01

54  
papers

2,358  
citations

218677

26  
h-index

214800

47  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3202  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , 2019, 9, 127.	4.8	262
2	Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. <i>Neuropharmacology</i> , 2013, 68, 184-194.	4.1	232
3	Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18736-18741.	7.1	160
4	Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. <i>Schizophrenia Research</i> , 2007, 91, 51-61.	2.0	137
5	An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. <i>Schizophrenia Research</i> , 2009, 111, 115-122.	2.0	117
6	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 119-135.	2.1	116
7	Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4407-4411.	7.1	102
8	Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. <i>Drugs</i> , 2017, 77, 381-401.	10.9	98
9	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. <i>Psychopharmacology</i> , 2018, 235, 3017-3030.	3.1	81
10	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. <i>Journal of Affective Disorders</i> , 2018, 231, 51-57.	4.1	62
11	Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 263, 568-575.	4.1	59
12	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 8-21.	2.1	58
13	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , 2019, 24, 2033-2043.	6.4	57
14	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. <i>Molecular Psychiatry</i> , 2021, 26, 3292-3301.	7.9	57
15	A Major Role for the Lateral Habenula in Depressive Illness: Physiologic and Molecular Mechanisms. <i>Frontiers in Psychiatry</i> , 2019, 10, 320.	2.6	50
16	DNA methyltransferases 1 (DNMT1) and 3a (DNMT3a) colocalize with GAD67 $\alpha$ -positive neurons in the GAD67 $\alpha$ -EGFP mouse brain. <i>Journal of Comparative Neurology</i> , 2012, 520, 1951-1964.	1.6	48
17	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. <i>Molecular Psychiatry</i> , 2018, 23, 1626-1631.	7.9	48
18	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. <i>Molecular Psychiatry</i> , 2021, 26, 4085-4095.	7.9	48

#	ARTICLE	IF	CITATIONS
19	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. <i>Neuropsychopharmacology</i> , 2020, 45, 1398-1404.	5.4	47
20	Characterizing the course of suicidal ideation response to ketamine. <i>Journal of Affective Disorders</i> , 2018, 241, 86-93.	4.1	44
21	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 417-425.	2.1	42
22	Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. <i>Neuropsychopharmacology</i> , 2020, 45, 982-989.	5.4	37
23	Selective $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons. <i>Neuropsychopharmacology</i> , 2011, 36, 1366-1374.	5.4	36
24	Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage. <i>Toxicology</i> , 2009, 256, 164-174.	4.2	31
25	Imidazenil: A low efficacy agonist at $\alpha 1$ - but high efficacy at $\alpha 5$ -GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. <i>Neuropharmacology</i> , 2008, 55, 148-153.	4.1	29
26	The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14169-14174.	7.1	26
27	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	4.8	26
28	Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road. <i>Drug Discovery Today</i> , 2021, 26, 2816-2838.	6.4	26
29	Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2239-2244.	7.1	23
30	Acute Imidazenil Treatment after the Onset of DFP-Induced Seizure Is More Effective and Longer Lasting than Midazolam at Preventing Seizure Activity and Brain Neuropathology. <i>Toxicological Sciences</i> , 2011, 120, 136-145.	3.1	21
31	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 0,8 21		
32	Neurobiological biomarkers of response to ketamine. <i>Advances in Pharmacology</i> , 2020, 89, 195-235.	2.0	21
33	Can "floating" predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. <i>Journal of Psychiatric Research</i> , 2020, 130, 280-285.	3.1	18
34	L-methionine decreases dendritic spine density in mouse frontal cortex. <i>NeuroReport</i> , 2010, 21, 543-548.	1.2	16
35	The effects of ketamine on typical and atypical depressive symptoms. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 394-401.	4.5	16
36	Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 383-389.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. <i>Journal of Affective Disorders</i> , 2021, 280, 136-139.	4.1	14
38	Disentangling the association of depression on the anti-fatigue effects of ketamine. <i>Journal of Affective Disorders</i> , 2019, 244, 42-45.	4.1	11
39	Absence of tolerance to the anticonvulsant and neuroprotective effects of imidazenil against DFP-induced seizure and neuronal damage. <i>Neuropharmacology</i> , 2011, 61, 1463-1469.	4.1	8
40	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. <i>Translational Psychiatry</i> , 2022, 12, 179.	4.8	8
41	Not So Fast. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	6
42	Pseudologia fantastica: Forensic and clinical treatment implications. <i>Comprehensive Psychiatry</i> , 2015, 56, 17-20.	3.1	4
43	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 141-167.	1.7	4
44	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 243-246.	1.4	3
45	330. A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression. <i>Biological Psychiatry</i> , 2017, 81, S135.	1.3	2
46	1004. Clinical Predictors of an Antisuicidal Response to Ketamine. <i>Biological Psychiatry</i> , 2017, 81, S406.	1.3	1
47	Do cognitive and neuropsychological functioning deficits coincide with hippocampal alteration during first-psychotic episode?. <i>CNS Spectrums</i> , 2019, 24, 472-478.	1.2	1
48	1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression. <i>Biological Psychiatry</i> , 2017, 81, S405-S406.	1.3	0
49	F171. Ketamine Modulates Kynurenine Pathway in Mood Disorders: A Longitudinal Structural Equation Model. <i>Biological Psychiatry</i> , 2018, 83, S304-S305.	1.3	0
50	S93. Ketamine Treatment Modulates the Kynurenine and Arginine Pathways in Depressed Unipolar and Bipolar Patients. <i>Biological Psychiatry</i> , 2019, 85, S333.	1.3	0
51	The Impact of Ketamine and AV-101 on the Kynurenine Pathway in Subjects With Treatment-Resistant Unipolar or Bipolar Depression. <i>Biological Psychiatry</i> , 2020, 87, S74.	1.3	0
52	Reply to: "Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightness are not the same" A comment on Acevedo-Diaz et al. (Jpsychiatres-D-21-00121). <i>Journal of Psychiatric Research</i> , 2021, 137, 409-410.	3.1	0
53	The Impact of NMDA Antagonists Ketamine and Prodrug 4-Chlorokynurenine (AV-101) in Subjects With Treatment-Resistant Mood Disorders. <i>Biological Psychiatry</i> , 2021, 89, S7.	1.3	0
54	Rapid-Acting Antidepressants. , 2019, , 218-240.		0